References
- Almer, G., et al. 2013. Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Molecular pharmaceutics, 10 (1), 175–186.
- Ambesh, P., et al. 2017. Nanomedicine in coronary artery disease. Indian heart journal, 69 (2), 244–251.
- Asadullah, K., Sterry, W., and Volk, H.D., 2003. Interleukin-10 therapy-review of a new approach. Pharmacological reviews, 55 (2), 241–269.
- Bozzuto, G. and Molinari, A., 2015. Liposomes as nanomedical devices. International journal of nanomedicine, 10, 975–999.
- Buttar, H.S., Li, T., and Ravi, N., 2005. Prevention of cardiovascular diseases: role of exercise, dietary interventions, obesity and smoking cessation. Experimental and clinical cardiology, 10 (4), 229–249.
- Caldorera-Moore, M., et al. 2010. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert opinion on drug delivery, 7 (4), 479–495.
- Chen, Y., et al. 2014. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation. Arteriosclerosis, thrombosis, and vascular biology, 34 (2), 365–376.
- Dwivedi, P., et al. 2019. Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. Materials science & engineering. C, materials for biological applications, 102, 113–123.
- Fleg, J.L., et al. 2012. Detection of high-risk atherosclerotic plaque: report of the NHLBI working group on current status and future directions. JACC: cardiovascular imaging, 5 (9), 941–955.
- Gupta, P.K., et al. 2014. Exploitation of lectinized lipo-polymerosome encapsulated amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis. Bioconjugate chemistry, 25 (6), 1091–1102.
- Katsuki, S., et al. 2017. Anti-inflammatory nanomedicine for cardiovascular disease. Frontiers in cardiovascular medicine, 4, 87–87.
- Khandelwal, K., et al. 2015. Improved oral bioavailability of novel antithrombotic S002-333 via chitosan coated liposomes: a pharmacokinetic assessment. RSC advances, 5 (49), 39168–39176.
- Kim, M., et al. 2020. Targeted delivery of anti-inflammatory cytokine by nanocarrier reduces atherosclerosis in Apo E-/- mice. Biomaterials, 226, 119550.
- Kotyla, P., 2010. The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology. Therapeutic advances in musculoskeletal disease, 2 (5), 257–269.
- Li, M.-C. and He, S.-H., 2004. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World journal of gastroenterology, 10 (5), 620–625.
- Mosser, D.M. and Zhang, X., 2008. Interleukin-10: new perspectives on an old cytokine. Immunological reviews, 226, 205–218.
- Nakhlband, A., et al. 2018. Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective. Bioimpacts, 8 (1), 59–75.
- Rafieian-Kopaei, M., et al. 2014. Atherosclerosis: process, indicators, risk factors and new hopes. International journal of preventive medicine, 5 (8), 927–946.
- Sakai, K., et al. 2018. Myeloid HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase determines atherosclerosis by modulating migration of macrophages. Arteriosclerosis, thrombosis, and vascular biology, 38 (11), 2590–2600.
- Sharma, K., Kumar, K., and Mishra, N., 2016. Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia. Drug delivery, 23 (3), 684–699.
- Zhaorigetu, S., et al. 2014. Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. Journal of liposome research, 24 (3), 182–190.